SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing renewed momentum driven by strong prescription data and positive sentiment surrounding the oral Wegovy rollout, which is being viewed as a strategic advantage against competitors. Investors are closely watching the upcoming earnings report, with community discussions heavily focused on the company's ability to maintain its market position through potential M&A and improved guidance.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened retail activity and speculative momentum driven by its integration into the broader Japanese blockchain and IoT data economy narratives. While the community is actively debating the potential impact of ecosystem expansions like Janction, sentiment remains divided between long-term holders accumulating positions and skeptics focused on historical price underperformance.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is seeing significant momentum and retail interest as investors connect the company's specialized MRAM technology to broader AI memory and aerospace growth narratives. Market participants are actively debating the sustainability of this rapid move, with bulls pointing to recent defense contracts and low float as catalysts for a potential squeeze, while some skeptics express concerns over high valuations and technical resistance.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Abbott Laboratories

Abbott Laboratories is experiencing significant downward pressure as investors weigh disappointing earnings guidance and the financial implications of its recent acquisition of Exact Sciences. The community is actively debating whether the current price levels represent a deep-value buying opportunity or a value trap amid ongoing litigation concerns and broader institutional de-risking within the healthcare sector.

Investment Managers Series Trust II - Tradr 2X Short SNDK Daily ETF

Tradr 2X Short SNDK Daily ETF

Tradr 2X Short SNDK Daily ETF (SNDQ) is seeing significant volume and trader attention as market participants attempt to hedge against the rapid, parabolic price appreciation in SanDisk (SNDK). The community is actively debating the sustainability of the semiconductor sector's momentum, with many users employing SNDQ as a tactical vehicle to bet on a potential correction or reversal.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following an FDA meeting to define the pivotal Phase 3 registration path for CAD-1005 in treating heparin-induced thrombocytopenia, though community sentiment remains polarized due to concerns over high-frequency social media spamming and future dilution risks.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending following a successful IPO that saw significant interest due to its strategic backing by Amazon and its position as a key infrastructure player in the AI power-demand narrative. The community is actively debating the company's valuation compared to peers, with investors highlighting the company's industrial partnerships and proprietary TRISO fuel technology as major differentiators for long-term scalability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as shareholders react to reports that FDA Commissioner Marty Makary may be replaced, a move widely interpreted by the community as a positive catalyst that could alleviate regulatory friction for the company's oncology pipeline. Investors are actively discussing the potential for smoother sBLA reviews and increased global expansion, fueling bullish sentiment despite recent volatility and ongoing legal disputes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors are intensely debating the sustainability of the semiconductor sector's parabolic rally, with many retail traders actively seeking entry points into leveraged bear positions like SOXS despite consistent losses from decay and sustained momentum. The community is sharply divided between those who believe the AI-driven 'super cycle' is a long-term wealth generator and those convinced the sector is a historic bubble fueled by unsustainable hype, circular financing, and extreme market manipulation.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares have surged following the company's disclosure of early-stage research into an mRNA-based vaccine for the rodent-borne hantavirus. The stock is currently a focus for traders betting on speculative momentum and potential pandemic-era dynamics, with active community discussion centering on vaccine platform versatility and ongoing oncology pipeline developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The partnership makes Medirom the operator for World ID verification across Japan.</li><li>Its rollout will use Medirom’s 300 locations, along with flagship and pop-up sites, to scale quickly.</li><li>Investors reacted positively to the prospect of a new, recurring revenue stream beyond wellness.</li></ul>Shares of Medirom Healthcare Technologies Inc. (MRM) jumped about 10% in after-hours trading on Friday after the company announced a partnership tied to OpenAI CEO Sam Altman’s World project, positioning Medirom as a key operator in Japan’s rollout of “Proof of Human” verification technology.<h2 class="st-heading-2">Medirom Picked To Operate World ID Locations In Japan</h2>Medirom said it has entered into a master service agreement with Tools for Humanity and the World Foundation to operate World’s “Proof of Human” verification locations across Japan. World is a biometric identity project co-created by Sam Altman and Alex Blania that aims to help users prove they are human online without revealing personal identity.Under the agreement, Medirom will be responsible for running verification sites using World’s technology, including the deployment of Orb devices that confirm humanness through privacy-preserving biometric methods.<h2 class="st-heading-2">Nationwide Rollout&nbsp;</h2>Medirom plans to use its nationwide footprint of roughly 300 locations to accelerate deployment. The company said it will also establish flagship verification sites and temporary pop-up locations in commercial and public spaces, supported by a newly formed internal task force dedicated to the project.The company expects the initiative to generate revenue over time through operating fees and related services as adoption scales.<h2 class="st-heading-2">‘Proof of Human’ Gains Focus Amid AI Boom</h2><a href="https://stocktwits.com/news-articles/markets/cryptocurrency/sam-altman-world-eye-scanning-startup-uk/chlEkYsRby1">World project was created</a> to address growing concerns that advances in AI are making it harder to distinguish humans from bots online. The project uses blockchain-based infrastructure to provide users with an anonymous World ID that can be used across participating platforms.Tools for Humanity, which led the initial development of the World project, said Japan’s high level of technology adoption makes it a key market for expanding digital identity infrastructure.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Medirom was ‘extremely bullish’ amid ‘high’ message volume.<figure class="image"><img style="aspect-ratio:974/141;" src="https://news.stocktwits-cdn.com/mrm_ss_png_f13ca655da.webp" alt="mrm ss.png" width="974" height="141"><figcaption>MRM sentiment and message volume as of December 26| Source: Stocktwits</figcaption></figure>One user said they can see the stock “rallying” next week.<stembedurl>https://stocktwits.com/squarellim/message/640209408</stembedurl><a href="https://stocktwits.com/symbol/MRM">Medirom’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the MEDIROM Healthcare Technologies logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Medirom Stock Jumps 10% After Hours On Deal To Run Sam Altman’s World ‘Proof Of Human’ Sites In Japan

The deal positions Medirom at the center of Japan’s push to deploy human-verification infrastructure as AI adoption accelerates.

Equity

MEDIROM Healthcare Technologies (NYSE:MRM) Trading 2.8% Higher - Here's Why

MEDIROM Healthcare Technologies (NYSE:MRM) Trading 2.8% Higher - Here's Why...

MEDIROM Healthcare Technologies (NYSE:MRM) Stock Price Up 1% - Should You Buy?

MEDIROM Healthcare Technologies (NYSE:MRM) Trading 1% Higher - Here's Why...

MEDIROM Healthcare Technologies (NYSE:MRM) Trading 1.6% Higher - What's Next?

MEDIROM Healthcare Technologies (NYSE:MRM) Trading Up 1.6% - Should You Buy...

Shares of Medirom Healthcare Technologies surged over 250% in premarket trading on Friday after the Tokyo-based wellness and healthtech company announced a partnership with World, the “proof of human” protocol co-founded by OpenAI’s Sam Altman and Alex Blania of Tools for Humanity.Medirom said it will install World ID’s Orb authentication devices across 100 of its Re.Ra.Ku relaxation studios in Japan this month, expanding to 200 locations nationwide. The rollout represents the largest Orb deployment in Japan so far, aimed at providing broad access to a system that verifies individuals’ “humanness” without revealing their identity.The Orb, an advanced imaging device, issues a World ID once verification is complete, which is stored in the World App for use across compatible services. Medirom said its integration of the devices underscores its push to fuse healthcare with technology while accelerating World ID adoption in Japan.The company operates over 300 wellness salons under various brands, including Re.Ra.Ku, Spa Re.Ra.Ku, and Bell Epoc, and also develops digital health solutions, including the Lav training app and the Mother Bracelet, a battery-free smart tracker used in industries from caregiving to construction.On Stocktwits, retail sentiment for Medirom was ‘extremely bullish’ amid ‘extremely high’ message volume.Some retail traders speculated on sharp price targets for Medirom, with one suggesting the stock could open at around $7, while another said it might climb to $10 during the session.<stembedurl>https://stocktwits.com/madstocks123/message/630074517</stembedurl><stembedurl>https://stocktwits.com/HellenicRenegade/message/630087145</stembedurl><a href="https://stocktwits.com/symbol/MRM">Medirom’s stock</a> has risen nearly 41% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Medirom Healthcare Technologies Stock Surging Over 250% Premarket Today?

The surge followed news that Medirom will deploy Sam Altman’s World ID Orb devices across its Re.Ra.Ku studios in Japan.

Medirom Healthcare Technologies ($MRM) ADR shares were down 12% on Monday, even as the Japan-based wellness salon operator announced a series A equity raise by its subsidiary.Medirom subsidiary Medirom Mother Labs Inc. has raised an aggregate total of 260.3 million yen, or about $1.7 million, at a pre-money equity valuation of JPY9 billion, or about $58.6 million in its Series A equity financing, the company said in a statement.The firm noted NFES Technologies Inc. was the lead investor in the financing round, along with several other public companies in Japan, including M3 Inc. and Elematec Corp. Certain individual investors also participated in the round. Medirom Mother Labs has closed financings with six investors to date and hopes to complete this round by December 31.“We are very excited that our Medirom Mother Labs subsidiary has received such significant validation from strategic partners as our lead investor NFES Technologies Inc.,” Kouji Eguchi, Medirom’s CEO, said in a statement. “The pre-money valuation of 9 billion yen is approximately multiples of Medirom’s current NASDAQ listing market capitalization…further validates our technology, business model, and growth potential.” Retail chatter on Stocktwits indicated a mixed take on the stock.<stembedurl>https://stocktwits.com/HumbleTrader187/message/596459081</stembedurl><stembedurl>https://stocktwits.com/biff1/message/596382806</stembedurl><stembedurl>https://stocktwits.com/Z_interceptor/message/596439765</stembedurl>Medirom operates over 300 wellness salons across Japan under its Re.Ra.Ku brand.Shares of the firm are down 80% year-to-date.(Calculations based on an exchange rate of JPY153.64 to $1)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medirom Healthcare Stock Dips On Series A Equity Raise: Retail’s Divided

 NFES Technologies Inc. is the lead investor in the latest financing round.

MEDIROM Healthcare Technologies, Inc. owns, develops, operates, manages, and supports relaxation salons through the franchising and direct ownership of such salons. It provides relaxation and bodywork services. The firm operates two synergistic lines of businesses: Relaxation Salon Segment (retail) and Digital Preventative Healthcare Segment (healthtech). The company was founded by Kouji Eguchi on July 13, 2000 and is headquartered in Tokyo, Japan.

MEDIROM Healthcare Technologies Inc - ADR

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

MRM
MEDIROM Healthcare Technologies Inc - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest MRM News

MRMMEDIROM Healthcare Technologies Inc - ADR